CTIC stock forecast
Our latest prediction for CTI BioPharma Corp.'s stock price was made on the Feb. 9, 2018 when the stock price was at 3.21$.
In the short term (2weeks), CTIC's stock price should outperform the market by 3.89%. During that period the price should oscillate between -9.24% and +17.57%.
In the medium term (3months), CTIC's stock price should outperform the market by 8.13%. During that period the price should oscillate between -20.18% and +49.12%.Get email alerts
About CTI BioPharma Corp.
CTI BioPharma Corp. is a biopharmaceutical company, which focuses on the development, acquisition and commercialization of novel targeted therapies for blood-related cancers. It focuses on evaluating pacritinib, its sole product candidate currently in active development, for the treatment of adult patients with myelofibrosis. The company was founded by James A. Bianco, Jack W. Singer, and Louis A. Bianco in September 1991 and is headquartered in Seattle, WA.
At the moment the company generates 12M USD in revenues.
On its last earning announcement, the company reported a loss of -0.89$ per share.
The book value per share is 1.20$
Three months stock forecastFeb. 9, 2018
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|